Valuing prodromal psychosis: What do we get and what is the price?

References 

1. Berger G, Wood SJ, Dell'olio M, Hamer C, Phillips L, Nelson B, et al. Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Schizophrenia Research. 2008;102 (1–3)(Suppl. 2):39–40
2. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Archives of General Psychiatry. 2002;59(5):449–456
   • MEDLINE
3. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry. 2008;65(1):28–37
4. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. Journal of Clinical Psychiatry. 2007;68:546–557
5. French P, Shryane N, Bentall RP, Lewis SW, Morrison AP. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. British Journal of Psychiatry, Supplementum. 2007;51:s82–s87
6. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry. 2009;66(1):13–20
7. Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. British Journal of Psychiatry. 2004;185:298–305
8. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry. 2001;58(2):158–164
   • MEDLINE
9. Krabbendam L, Myin-Germeys I, De Graaf R, Vollebergh W, Nolen WA, Iedema J, et al. Dimensions of depression, mania and psychosis in the general population. Psychological Medicine. 2004;34(7):1177–1186
   • MEDLINE
10. Krabbendam L, Myin-Germeys I, Hanssen M, de Graaf R, Vollebergh W, Bak M, et al. Development of depressed mood predicts onset of psychotic disorder in individuals who report hallucinatory experiences. British Journal of Clinical Psychology. 2005;44(1):113–125
11. McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, et al. Recruitment and treatment practices for help-seeking “prodromal” patients. Schizophrenia Bulletin. 2007;33(3):715–726
    • MEDLINE
12. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry. 2002;59(10):921–928
    • MEDLINE
13. McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophrenia Bulletin. 2003;29(4):771–790
    • MEDLINE
14. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. Journal of Clinical Psychiatry. 2009;70(9):1206–1212
15. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry. 2004;185:291–297
16. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin. 2007;33(3):682–687
    • MEDLINE
17. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research. 2007;96:25–33
    • Abstract
    • Full Text
    • Full-Text PDF (250 KB)
18. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(Suppl 3):S162–S167
19. Simon AE, Dvorsky DN, Boesch J, Roth B, Isler E, Schueler P, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophrenia Research. 2006;81:83–90
    • Abstract
    • Full Text
    • Full-Text PDF (116 KB)
20. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Archives of General Psychiatry. 2001;58(7):663–668
    • MEDLINE
21. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness–persistence–impairment model of psychotic disorder. Psychological Medicine. 2009;39(2):179–195
22. Woods S, Addington J, Cadenhead K, Cannon T, Cornblatt B, Heinssen B, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American prodrome longitudinal study. Schizophrenia Bulletin. 2009;894–908
23. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophrenia Research. 2003;60(1):21–32
    • Full-Text PDF (131 KB)
24. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research. 2004;67(2–3):131–142
    • Abstract
    • Full Text
    • Full-Text PDF (197 KB)